Results 11 to 20 of about 7,294 (204)

Antiparasitic Drugs in the United States—Two Roads to High Prices

Frontiers in Sociology, 2020
High prescription drug prices contribute significantly to healthcare spending in the United States and compromise patients' access to quality medical care.
Arman A. Shahriar, Jonathan D. Alpern, Jonathan D. Alpern   +2 more
doaj   +1 more source

Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications [PDF]

Journal of Primary Health Care, 2022
IntroductionNew medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand.
Caroline Stretton, Charon Lessing, Farzana Sarkisova   +2 more
doaj  

Constructing a Real-Time Prescription Drug Monitoring System [PDF]

Healthcare Informatics Research, 2016
ObjectivesThe objective of this investigation was to demonstrate the possibility of the construction of a real-time prescription drug monitoring system (PDMOS) using data from the nationwide Drug Utilization Review (DUR) system in Korea.MethodsThe DUR ...
Young-Taek Park, Youn Tae Lee, Emmanuel C. Jo   +2 more
doaj   +1 more source

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan.

PLOS Global Public Health, 2022
Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global Drug Facility, they can incur import costs for international transport,
Stefan Kohler, Norman Sitali, Jay Achar, Nicolas Paul   +3 more
doaj   +2 more sources

Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon

SAHARA-J, 2004
This paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon.
Kenneth Ngwambokong Muko, Valentine Che Ngwa, Leslie Chigang, Igbinosum Gladys Ngwa, Anke Meiburg, Elvis Neba Shu   +5 more
doaj   +1 more source

Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study

São Paulo Medical Journal, 2021
BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users’ direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs ...
Paula Becker, Denise Razzouk
doaj   +1 more source

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

Orphanet Journal of Rare Diseases, 2023
Background The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards.
Yankier Pijeira Perez, Eifiona Wood, Dyfrig A Hughes   +2 more
doaj   +1 more source

Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India

Indian Heart Journal, 2021
Background: Costs can be a major barrier to medication adherence in low and middle-income countries and are an important target for policy-level interventions.
Balaji Arvind, Anita Saxena, Dhruv S. Kazi, Ann F. Bolger   +3 more
doaj   +1 more source

Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits

Cancer Medicine, 2020
Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ)
Ambica Parmar, Tina Jiao, Ronak Saluja, Kelvin K. W. Chan   +3 more
doaj   +1 more source

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Current Oncology
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation.
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist   +14 more
doaj   +1 more source